Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
暂无分享,去创建一个
A. Grothey | M. Fakih | F. Ciardiello | Z. Wainberg | A. Sartore-Bianchi | S. Siena | F. Loupakis | K. Saxena | T. Yoshino | E. Elez | T. Nishina | Javier Rodríguez | K. Yamaguchi | Y. Komatsu | K. Chung | K. Raghav | H. Kawakami | T. Esaki | M. Di Bartolomeo | J. Shahidi | T. Masuishi | E. Yamamoto | E. Bako | Y. Okuda | E. Élez
[1] V. Torri,et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial , 2020, ESMO Open.
[2] V. Torri,et al. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. , 2020, Clinical colorectal cancer.
[3] Y. Bang,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.
[4] F. Ciardiello,et al. Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. , 2020, JAMA oncology.
[5] P. Jänne,et al. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. , 2020, Cancer discovery.
[6] Jing-Yuan Fang,et al. Comprehensive review of targeted therapy for colorectal cancer. , 2020, Signal transduction and targeted therapy.
[7] C. Redfern,et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Nakagawa,et al. [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification , 2019, International journal of cancer.
[9] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[10] N. Kemeny,et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial , 2019, Annals of Oncology.
[11] Yusuke Nakamura,et al. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study , 2019, Annals of Oncology.
[12] V. Torri,et al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. , 2019, The oncologist.
[13] H. Iwata,et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. , 2019, The Lancet. Oncology.
[14] C. Redfern,et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. , 2019, The Lancet. Oncology.
[15] J. Hainsworth,et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. , 2019, The Lancet. Oncology.
[16] Jeffrey S. Morris,et al. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. , 2019, JCO precision oncology.
[17] A. Bardelli,et al. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. , 2018, Cancer cell.
[18] T. Yamanaka,et al. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer , 2018, Clinical colorectal cancer.
[19] A. Bardelli,et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] James X. Sun,et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 , 2018, Cancer.
[21] J. Tabernero,et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] A. Kitano,et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. , 2017, The Lancet. Oncology.
[23] S. Kubicka,et al. Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies. , 2017, Cancer treatment reviews.
[24] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] T. Agatsuma,et al. Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.
[26] T. Agatsuma,et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.
[27] L. Sánchez-Lorenzo,et al. Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It , 2016, Clinical Medicine Insights. Oncology.
[28] Marc Peeters,et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.
[29] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[30] G. Sauter,et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. , 2010, Human pathology.